Complain about a product or service

Long-Term Aspirin Use May Reduce Heart-Related Deaths in Women

March 26, 2007

• Russert Death Has Americans Questioning Their Health • Many Cardiac Patients Don't Know Heart Attack Symptoms • Women Less Likely to Spot Heart Attack Warning Signs • Worst Time to Have a Heart Attack? • Children Face Increased Heart Risks • Heart Attack Victim Hounded For $5 Co-Pay • Heart, Stroke Death Rates Show Steady Decline • High Heart Attack, Stroke Risk in Aspirin-Resistant Patients • Calcium Supplements May Increase Older Women's Heart Risk • Hospitals Slow to Start Defibrillation • Heart Attack Symptoms May Differ in Women • Winter is Prime Time for Heart Attacks • Men More Likely To Change Unhealthy Habits Than Women • Study Evaluates U.S. News Hospital Ratings • Study: Obese Heart Attack Patients More Likely to Survive • Long-Term Aspirin Use May Reduce Heart-Related Deaths in Women • New Guidelines on Women's Lifetime Heart Risk • Women's Heart Risk Factors Need Updating • Midday Napping May Reduce Heart-Attack Risk • Women's Heart Disease Often Goes Undetected • MRI May Provide Early Warning Of Heart Attack • A Good Night's Sleep Essential to Heart Health • Simple Blood Test Might Warn Heart Attack & Stroke Victims • Cutting Job Stress Cuts Heart Risk • Hospitals Vow to Improve Heart Attack Response Time • Older Painkillers May Increase Heart Attack Risk • tudy Finds Aspirin Still Tops in Heart Attack & Stroke Prevention --- • More Health News ...

Women who take low to moderate doses of aspirin have a reduced risk of heart disease-related deaths, according to a report in the March 26 issue of Archives of Internal Medicine.

Some studies have provided evidence that aspirin may reduce the risk of heart disease and some types of cancer, the two leading causes of death in U.S. women.

"Use of aspirin for one to five years was associated with significant reductions in cardiovascular mortality," researchers wrote. "In contrast, a significant reduction in risk of cancer deaths was not observed until after 10 years of aspirin use.

The benefit associated with aspirin was confined to low and moderate doses and was significantly greater in older participants and those with more cardiac risk factors."

Andrew T. Chan, M.D., M.P.H., Massachusetts General Hospital and Harvard Medical School, Boston, and colleagues examined the association between aspirin use and death in 79,439 women enrolled in the Nurses' Health Study, a large group of female nurses who have been followed since 1976.

Beginning in 1980 and again every two years through 2004, the women were asked if they used aspirin regularly and if so, how many tablets they typically took per week. At the beginning of the study, the women had no history of cardiovascular disease or cancer.

A total of 45,305 women did not use aspirin; 29,132 took low to moderate doses (one to 14 standard 325-milligram tablets of aspirin per week); and 5,002 took more than 14 tablets per week. By June 1, 2004, 9,477 of the women had died, 1,991 of heart disease and 4,469 of cancer.

The association was stronger for death from cardiovascular disease (women who used aspirin had a 38 percent lower risk) than for death from cancer (women who used aspirin had a 12 percent lower risk).

There are several mechanisms by which aspirin could reduce the risk of death, the authors note. "Aspirin therapy may influence cardiovascular disease and cancer through its effect on common pathogenic pathways such as inflammation, insulin resistance, oxidative stress [damage to the cells caused by oxygen exposure] and cyclooxygenase (COX) enzyme activity," also linked to inflammation, they write.

Because the study looked at women who made the decision themselves whether or not to take aspirin, as opposed to a clinical trial where women are randomly assigned to aspirin or a placebo, the results do not suggest that all women should take aspirin.

"Nevertheless, these data support a need for continued investigation of the use of aspirin for chronic disease prevention," the authors conclude.

In an accompanying editorial John A. Baron, M.D., Dartmouth Medical School, Lebanon, N.H., points out that in the Women's Health Study, researchers followed almost 40,000 women for 11 years and did not find any reduced risk of cardiovascular or other death associated with aspirin therapy, in contrast to the dramatic risk reduction seen in the Nurses' Health Study.

"Is aspirin really that good or is there some other explanation for the findings that differ so much from those of the WHS and other primary prevention trials?" he writes.

"The difference between the NHS and the aggregated data from the WHS and other trials is too large to be explained by potential weaknesses in the randomized studies," Dr. Baron writes. "At the same time, one has to consider that the observational NHS may not have been able to deal with the differences between aspirin users and non-users."

"Therefore, these new findings by Chan et al cannot overcome the accumulated evidence that aspirin is not particularly effective for the primary prevention of death from cardiovascular disease in women," he concludes.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.